Last reviewed · How we verify
Nivolumab,low dose cyclophosphamide
At a glance
| Generic name | Nivolumab,low dose cyclophosphamide |
|---|---|
| Sponsor | Hadassah Medical Organization |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma (PHASE3)
- Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas (PHASE2)
- Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1 (PHASE1)
- Personalized DC Vaccines in Non Small Cell Lung Cancer (PHASE1)
- Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC) (PHASE2)
- Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer (PHASE1, PHASE2)
- Nivolumab Combined With Daratumumab With or Without Low-dose Cyclophosphamide (PHASE2)
- Adoptive Tumor-infiltrating Lymphocyte Transfer With Nivolumab for Melanoma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: